Rapport Therapeutics Slides on Stock and Convertible Note Offerings
Rapport Therapeutics shares fall after announcing a $200 million stock offering, $150 million of convertible notes and a private placement.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Dow Jones Newswires reports that Rapport Therapeutics shares declined after the company announced a $200 million stock offering, $150 million of convertible notes and a private placement. After hours the stock fell 19% to $22.19. At the regular market close, the shares were down about 9% for the year so far.
Rapport develops drugs for patients with neurological and psychiatric disorders. Its lead candidate, RAP-219, is designed to act on selected brain regions by targeting a receptor-associated protein found only in specific areas of the brain. Last week the company reported positive Phase 2 results for RAP-219 in adults with acute bipolar mania.
The convertible notes are due December 1, 2032, unless they are converted, redeemed or repurchased earlier.
why it matters
New shares and convertible debt increase the number of shares outstanding and dilute existing holders, which typically weighs on the stock in the short term.
market impact
Rapport Therapeutics shares: new securities issuance adds pressure on the stock price
- Rapport Therapeutics shares pressure down — new stock and convertible notes dilute existing shareholders
tags
instruments
sources
- Rapport Therapeutics Down on Stock and Note Offerings — Dow Jones Newswires, 27 October 2026 at 22:18 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗